Sexually transmitted diseases and human immunodeficiency virus control in Malawi: a field study of genital ulcer disease

J Infect Dis. 1995 Feb;171(2):451-5. doi: 10.1093/infdis/171.2.451.

Abstract

Men with genital ulcer disease (GUD) attending a clinic in Malawi were evaluated and treated with one of five drug regimens. Haemophilus ducreyi was isolated from 204 (26.2%) of 778 patients. Of 677 men, 198 (29.2%) had treponemes detected in ulcer material by direct immunofluorescence or had rapid plasma reagin reactivity of > or = 1:8. Human immunodeficiency virus type 1 (HIV-1) seroprevalence was 58.9% overall and 75.8% among patients reporting a history of GUD (P < .001). By logistic regression analysis, HIV-1 seropositivity was shown to impair ulcer healing (P = .003). Treatment failure rates for culture-proven chancroid were 19% for trimethoprim-sulfamethoxazole, 12.9% and 7.4%, respectively, for low- and high-dose erythromycin regimens, and 8.3% and 0, respectively, for low- and high-dose ciprofloxacin regimens. Herpes antigen was detected by EIA in 6 (23.1%) of 26 nonhealing ulcers. In Malawi, GUD should be managed as a syndrome to assure treatment of both syphilis and chancroid.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Chancroid / drug therapy
  • Chancroid / epidemiology*
  • Ciprofloxacin / therapeutic use
  • Erythromycin / therapeutic use
  • Genital Diseases, Male / drug therapy
  • Genital Diseases, Male / epidemiology*
  • HIV Infections / prevention & control*
  • Humans
  • Malawi / epidemiology
  • Male
  • Penicillin G Benzathine
  • Skin Ulcer / drug therapy
  • Skin Ulcer / epidemiology*
  • Sulfamethoxazole / therapeutic use
  • Syphilis / drug therapy
  • Syphilis / epidemiology*
  • Trimethoprim / therapeutic use

Substances

  • Ciprofloxacin
  • Erythromycin
  • Trimethoprim
  • Sulfamethoxazole
  • Penicillin G Benzathine